155 related articles for article (PubMed ID: 21965163)
1. Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.
Tanigawa G; Kawashima A; Yamaguchi S; Nishimura K; Miyoshi S; Kajikawa J; Meguro N; Yosioka T; Oka T; Hara T; Takayama H; Nonomura N;
Jpn J Clin Oncol; 2011 Nov; 41(11):1265-70. PubMed ID: 21965163
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
4. Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.
Zhang H; Dong B; Lu JJ; Yao X; Zhang S; Dai B; Shen Y; Zhu Y; Ye D; Huang Y
BMC Cancer; 2009 Jul; 9():249. PubMed ID: 19622166
[TBL] [Abstract][Full Text] [Related]
5. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.
Feinberg BA; Jolly P; Wang ST; Fortner B; Scott J; Gilmore J; Neary MP; Duh MS
Med Oncol; 2012 Jun; 29(2):786-94. PubMed ID: 21479699
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.
Zhang Y; Li Y; Cai Y; Wang K; Li H
Cell Oncol (Dordr); 2016 Feb; 39(1):15-21. PubMed ID: 26597814
[TBL] [Abstract][Full Text] [Related]
7. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
8. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib in advanced clear-cell renal-cell carcinoma.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Siebels M; Negrier S; Chevreau C; Solska E; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Freeman S; Schwartz B; Shan M; Simantov R; Bukowski RM;
N Engl J Med; 2007 Jan; 356(2):125-34. PubMed ID: 17215530
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.
Eisen T; Oudard S; Szczylik C; Gravis G; Heinzer H; Middleton R; Cihon F; Anderson S; Shah S; Bukowski R; Escudier B;
J Natl Cancer Inst; 2008 Oct; 100(20):1454-63. PubMed ID: 18840822
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
[TBL] [Abstract][Full Text] [Related]
13. Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
Nakano K; Komatsu K; Kubo T; Natsui S; Nukui A; Kurokawa S; Kobayashi M; Morita T
Jpn J Clin Oncol; 2013 Oct; 43(10):1023-9. PubMed ID: 23956442
[TBL] [Abstract][Full Text] [Related]
14. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
Beck J; Procopio G; Bajetta E; Keilholz U; Negrier S; Szczylik C; Bokemeyer C; Bracarda S; Richel DJ; Staehler M; Strauss UP; Mersmann S; Burock K; Escudier B
Ann Oncol; 2011 Aug; 22(8):1812-23. PubMed ID: 21324953
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
Kondo T; Nakazawa H; Oya M; Kimura G; Fujii Y; Hatano T; Kawata N; Kume H; Morita M; Nakajima K; Ohno Y; Okegawa T; Takahashi S; Wakumoto Y; Horie S; Yamaguchi R; Saito K; Murakami M
Jpn J Clin Oncol; 2015 Mar; 45(3):274-80. PubMed ID: 25420693
[TBL] [Abstract][Full Text] [Related]
16. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Rini B; Szczylik C; Tannir NM; Koralewski P; Tomczak P; Deptala A; Dirix LY; Fishman M; Ramlau R; Ravaud A; Rogowski W; Kracht K; Sun YN; Bass MB; Puhlmann M; Escudier B
Cancer; 2012 Dec; 118(24):6152-61. PubMed ID: 22692704
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
Khan G; Golshayan A; Elson P; Wood L; Garcia J; Bukowski R; Rini B
Ann Oncol; 2010 Aug; 21(8):1618-1622. PubMed ID: 20089567
[TBL] [Abstract][Full Text] [Related]
18. Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
Trask PC; Bushmakin AG; Cappelleri JC; Tarazi J; Rosbrook B; Bycott P; Kim S; Stadler WM; Rini B
J Cancer Surviv; 2011 Sep; 5(3):255-62. PubMed ID: 21476015
[TBL] [Abstract][Full Text] [Related]
19. Experience with sorafenib and the elderly patient.
Dutcher JP; Tannir N; Bellmunt J; Escudier B
Med Oncol; 2010 Dec; 27(4):1359-70. PubMed ID: 20043216
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Garcia JA; Hutson TE; Elson P; Cowey CL; Gilligan T; Nemec C; Dreicer R; Bukowski RM; Rini BI
Cancer; 2010 Dec; 116(23):5383-90. PubMed ID: 20806321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]